AstriVax
PrivateLast Round
Grant
Dec 12, 2023
Total Funding Raised
$40.82M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
AstriVax is a clinical-stage biopharmaceutical company developing DNA-based, plug-and-play vaccine and immunotherapy platforms for infectious diseases and virus-driven cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AstriVax Comparables
Compare AstriVax with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hookipa Pharma | 81% | |
| Virion Therapeutics, LLC | 78% | |
| Barinthus Biotherapeutics | 77% |
For institutional investors. Book with your work email.
AstriVax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 12, 2023 | ||||
| Grant | May 30, 2023 | ||||
| Seed | Aug 25, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AstriVax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ackermans & van Haaren | Seed |
| Fund+ | Seed |
| KU Leuven Research & Development (LRD) | Seed |
| Korys | Seed |
| Thuja Capital | Seed |
| V-Bio Ventures | Seed |
| VLAIO | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 76% MoM.
- Jun 12, 2025
Dieter Weinand appointed Chair of the Board of Directors.
For institutional investors. Book with your work email.
AstriVax Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AstriVax's valuation, stock price, and market status.
Is AstriVax a public or private company?
AstriVax is a private company.
What is the current stock price of AstriVax?
AstriVax is a private company, so its shares have no public market price. Caplight tracks AstriVax's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AstriVax worth (valuation)?
Valuation information for AstriVax is not publicly available.
Can I buy AstriVax stock?
AstriVax shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AstriVax's last funding round?
AstriVax's most recent funding round was Grant on December 12, 2023.
Who are the main investors in AstriVax?
Key investors in AstriVax include Fund+, V-Bio Ventures.
Will AstriVax IPO soon?
No public IPO plans have been announced for AstriVax.
How can I track AstriVax secondary market activity?
Caplight tracks bids, offers, and trades in AstriVax's shares on secondary markets.